News for Shionogi & Co., Ltd. (SH0.F)

Reported positive interim data from Phase 3 open-label SHORELINE Study showing that more than 70% of patients successfully treated with zuranolone 30 mg needed two or fewer treatment courses over one... | February 24, 2021

The following slide deck was published by Shionogi & Co., Ltd. in conjunction with their 2021 Q3 earnings call..

Shionogi & Co has sold the development and marketing rights for a COVID-19 treatment to California-based biotech BioAge Labs Inc, the Japanese drugmaker said on Tuesday. Shionogi... | January 26, 2021